Mizuho Securities analyst Graig Suvannavejh initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) with a Buy rating and a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage

EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 17cNovember 1, 2023 7:22 AM Form 8-K EyePoint Pharmaceuticals For: Nov 01November 1, 2023 7:06 AM EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023October 31, 2023 7:00 AM Form EFFECT EyePoint Pharmaceuticals October 31, 2023 6:06 AM EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim’s 5th Annual Inflammation, Neurology & Immunology ConfOctober 30, 2023 7:00 AM